AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Psychedelicalpha

Published November 13, 2026 · Updated November 14, 2026

Field Notes #6: Dispatches from D.C. as Three Psychedelics Land at FDA

Read the full story at Psychedelicalpha

This week's HHS ibogaine announcement, NIMH's funding opportunity, and Delix's J&J-backed raise. A transcript is available below. Join Today.

Post on X

Share this story

Surfaced by this Google Alert

Ibogaine